Novo, Orbis sign up to $1.4 billion deal to develop oral drugs
By Siddhi Mahatole Sept 17 (Reuters) – Orbis Medicines said on Thursday it had signed a drug discovery and licensing agreement worth up to $1.4 billion with Novo Nordisk to develop oral therapies for cardiometabolic diseases, traditionally treated with injectable drugs. Here are the details: • The d
























